Dr. Anne W. Beaven
Claim this profileUNC Lineberger Comprehensive Cancer Center
Area of expertise
Mantle Cell Lymphoma
Anne W. Beaven has run 5 trials for Mantle Cell Lymphoma. Some of their research focus areas include:
Lymphoma
Anne W. Beaven has run 5 trials for Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
UNC Lineberger Comprehensive Cancer Center
Lineberger Comprehensive Cancer Center At University Of North Carolina
Clinical Trials Anne W. Beaven is currently running
Zanubrutinib
for Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting
2 awards
Phase 3
10 criteria
CD30 CAR T-Cell Therapy
for Lymphoma
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that carry the CD30 antigen. Once they are attached, the hope is that the T cells will attack and destroy the lymphoma cancer cells. To prepare the body for the ATLCAR.CD30 cells, participants will complete lymphodepletion with two chemotherapy agents. Lymphodepletion will happen over three days prior to ATLCAR.CD30 infusion. If participants respond to this treatment, and there are sufficient unused ATLCAR.CD 30 cells, they may be eligible to receive a second infusion. The second infusion will be given after a second lymphodepletion chemotherapy. Most of the clinic visits in this research will last between 1-8 hours. There are risks associated in participating in this research study. Risks of treatment include infection, fever, nausea, vomiting, neurotoxicity, and cytokine release syndrome which can include low blood pressure or difficulty breathing. Other risks are associated with study procedures, such as biopsies, imaging, infusion, and breach of confidentiality.
Recruiting
1 award
Phase 2
10 criteria
More about Anne W. Beaven
Clinical Trial Related
8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Anne W. Beaven has experience with
- Rituximab
- Cyclophosphamide
- Bendamustine
- Nivolumab
- Prednisone
- Cytarabine
Breakdown of trials Anne W. Beaven has run
Mantle Cell Lymphoma
Lymphoma
Hodgkin's Lymphoma
Peripheral T-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anne W. Beaven specialize in?
Anne W. Beaven focuses on Mantle Cell Lymphoma and Lymphoma. In particular, much of their work with Mantle Cell Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Anne W. Beaven currently recruiting for clinical trials?
Yes, Anne W. Beaven is currently recruiting for 3 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Anne W. Beaven has studied deeply?
Yes, Anne W. Beaven has studied treatments such as Rituximab, Cyclophosphamide, Bendamustine.
What is the best way to schedule an appointment with Anne W. Beaven?
Apply for one of the trials that Anne W. Beaven is conducting.
What is the office address of Anne W. Beaven?
The office of Anne W. Beaven is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.